One of the key issues that cultured meat companies face is scaling their offering, enabling them to produce more food and ultimately drive costs to the consumer down. Now, CellulaREvolution, a company based in the Northeast of England, says it has a solution and has raised £1 million to develop it.
The company believes that its technologies will enable the cultured meat industry to produce at real scale and at affordable costs and will ultimately be contributing to the far-reaching environmental and ethical benefits the lab-meat industry’s champions believe it will deliver.
Crucially CellulaREvolution is interesting the cultured meat community for among the investors which include Stephan Schmidt, Orange Light Ventures, and funds managed by Northstar Ventures, the North East Innovation Fund supported by the European Regional Development Fund and the newly launched Northern Accelerator Seed Investment Fund (NASIF), is CPT Capital. The London-based fund has backed many of the world’s leading cultured meat pioneers including Memphis Meats, Aleph Farms and Blue Nalu.
The investors said “CPT Capital are genuinely excited to be able to support CellulaREvolution in this financing round. The work that they are doing is of critical importance in establishing cultivated meat as a realistic, viable and attractive alternative to factory farming in meeting the world’s growing demand for food”
CellulaREvolution is a spin out from Newcastle University, and was founded in 2019 by Martina Miotto, Che Connon and Leo Groenewegen. Its key ground-breaking technology is to make the culturing of cells more efficient and affordable. The process is based on the novel concept of a continuous cell culturing system which has a higher yield, smaller footprint and lower input requirements than traditional batch technologies.
To date, CellulaREvolution has identified potential benefits from their technologies within the medical and pharmaceutical industries.
Leo Groenewegen CEO of CellulaREvolution said “The investment is a clear sign that investors both understand and believe the technological advantage our future products will have over others in this rapidly expanding market. We are now ready and equipped to accelerate the development of our products and make a true innovative impact on the way cells are grown!”
